Randomized, OpenLabel, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum Doublet Chemotherapy in Early Stage NSCLC
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CheckMate 816
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 07 Mar 2017 Planned End Date changed from 1 Jan 2024 to 1 Mar 2024.
- 07 Mar 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Sep 2019.